Effect of moderate hepatic impairment (MHI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK)
Rashmi Mehta, Kelly Hardes, Dennis Kelleher, Andrew Preece, Lee Tombs, Noushin Brealey
European Respiratory Journal 2013 42: P3641; DOI:
Rashmi Mehta
1Clinical Pharmacology Modeling and Simulation, GlaxoSmithKline, Research Triangle Park, United States
Kelly Hardes
2Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, Stockley Park, United Kingdom
Dennis Kelleher
3Respiratory Medicines Development Center, GlaxoSmithKline, Research Triangle Park, United States
Andrew Preece
2Clinical Pharmacology Science and Study Operations, GlaxoSmithKline, Stockley Park, United Kingdom
Lee Tombs
4Statistics and Progamming, Synergy, Slough, United Kingdom
Noushin Brealey
5Respiratory Medicines Development Centre, GlaxoSmithKline, Stockley Park, United Kingdom
Vol 42 Issue Suppl 57
Table of Contents
Effect of moderate hepatic impairment (MHI) on umeclidinium (UMEC) and vilanterol (VI) pharmacokinetics (PK)
Rashmi Mehta, Kelly Hardes, Dennis Kelleher, Andrew Preece, Lee Tombs, Noushin Brealey
European Respiratory Journal Sep 2013, 42 (Suppl 57) P3641;